Enhancing ARIC Infrastructure to Yield a New Cancer Epidemiology Cohort

描述（由申请人提供）：我们建议加强ARIC的基础设施;社区动脉粥样硬化风险，队列产生一个新的癌症流行病学队列，为癌症流行病学研究带来新的功能。1987年，从福赛斯公司招募了15,792名年龄在45-64岁之间的参与者，北卡罗来纳州;密西西比州杰克逊;明尼苏达州明尼阿波利斯;和华盛顿公司，马里兰州55%是女性，27%是非洲裔美国人。参与者接受了4次临床检查;第5次定于2011年进行。血液和尿液样本已被储存，药物记录，并完成了食物频率问卷。参与者每年接受一次电话采访，现在每半年一次，以获得最新的健康信息。第21年的回答率为91%。由于ARIC从未被视为癌症流行病学队列，以及基础设施和成本限制，只有癌症诊断被系统记录。到2006年，有3,145名参与者被诊断为第一次初级事故，376名参与者被诊断为第二次/第三次初级事故。目前还没有解决当代问题所需的信息，如分期、分级和组织学、器官位置、偏侧性、受体状态、治疗、复发和再治疗。尚未收集分子/遗传研究所需的组织。 因此，我们建议：1）从2012年开始，从每半年一次的电话访谈中前瞻性地识别病例，并收集与癌症诊断、治疗、复发和再治疗以及组织块有关的医疗/病理记录。2)回顾性收集2012年之前来自4个ARIC州（已获得知情同意）癌症登记处和医疗记录的表征癌症诊断和复发的信息，并收集组织块。到2016年，我们预计将有4,900个完全注释的事件案例。我们成立了一个癌症工作组，以制定裁定癌症终点的协议，并优先考虑使用该资源的研究。随着基础设施的增强，我们预计诸如这些的研究问题在ARIC中是唯一可解决的：1）使用4个空腹葡萄糖和2个HbAlc测量的糖尿病自然史的时间与癌症诊断的时间之间的关联是什么？2)使用GWAS和测序数据，是否存在一组主要癌症共有的风险变体，或者每个位点都有特定的变体？

DESCRIPTION (provided by applicant): We propose to enhance the infrastructure of ARIC; the Atherosclerosis Risk in Communities, cohort to yield a new Cancer Epidemiology Cohort that brings novel features to cancer epidemiology research. In 1987, 15,792 participants aged 45-64 years were recruited from Forsyth Co., NC; Jackson, MS; Minneapolis, MN; and Washington Co., MD. 55% are women and 27% are African-American. Participants underwent 4 clinical exams; a 5th is scheduled for 2011. Blood and urine specimens have been banked, medications recorded, and a food frequency questionnaire completed. Participants were interviewed by phone annually and now semi-annually to obtain updated health information. The response at year 21 is 91%. Because ARIC has never been viewed as a Cancer Epidemiology Cohort and infrastructure and cost constraints, only cancer diagnosis has been systematically recorded. By 2006, 3,145 participants were diagnosed with an incident first primary and 376 with a 2nd / 3rd primary. Information, such as stage, grade, and histology, location in organ, laterality, receptor status, treatment, recurrence, and re-treatment, needed to address contemporary questions is not currently available. Tissue needed for molecular/genetic studies has not been collected. Thus, we propose: 1) Starting 2012, to prospectively identify cases from semi-annual phone interviews and collect medical/pathology records pertaining to cancer diagnosis, treatment, recurrence, and retreatment and tissue blocks. 2) To retrospectively collect information characterizing cancer diagnoses and recurrences before 2012 from cancer registries in the 4 ARIC states (consent already obtained) and medical records, and collect tissue blocks. By 2016, we expect 4,900 fully annotated incident cases. We established a Cancer Working Group to develop protocols for adjudicating cancer endpoints and prioritize research using the resource. With enhanced infrastructure, we expect that research questions such as these are addressable uniquely in ARIC: 1) What is the association between timing of the natural history of diabetes using 4 fasting glucose and 2 HbAlc measurements and timing of cancer diagnosis? 2) Using GWAS and sequencing data, is there a set of risk variants shared by major cancers or are variants specific to each site?